As evidence accumulates, the guidelines may increasingly incorporate biomarkers; the American Heart Association has already noted in a scientific statement that risk assessment in diabetes may include biomarkers such as coronary calcium or CRP in selected patients [1]. This evidence concerns the gene CRP and diabetes mellitus.